AbbVie (ABBV) Capital Expenditures (2012 - 2026)
AbbVie (ABBV) posted quarterly Capital Expenditures of $265.0 million for Q1 2026, up 12.77% year-over-year from $235.0 million in Q1 2025, and down 19.45% quarter-over-quarter from $329.0 million in Q4 2025.
AbbVie (ABBV) Capital Expenditures (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Capital Expenditures for 15 consecutive years, with $265.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 12.77% year-over-year to $265.0 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 22.44% YoY), while the FY2025 annual figure was $1.2 billion, up 24.64% from the prior year.
- Capital Expenditures fell to $265.0 million in Q1 2026 per ABBV's latest filing, from $329.0 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $381.0 million in Q3 2025 and bottomed at $143.0 million in Q2 2022.
- Historically, Capital Expenditures has averaged $230.9 million across 5 years, with a median of $219.0 million in 2023.
- Annual changes were most pronounced in 2022 — Capital Expenditures dropped 26.67% — and 2025, when it jumped 53.01%.
- AbbVie's Capital Expenditures stood at $213.0 million in 2022, then slipped by 3.76% to $205.0 million in 2023, then soared by 41.95% to $291.0 million in 2024, then climbed by 13.06% to $329.0 million in 2025, then decreased by 19.45% to $265.0 million in 2026.
- Business Quant data shows ABBV's Capital Expenditures at $265.0 million in Q1 2026, $329.0 million in Q4 2025, and $381.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.53 Bn | 631.77 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 469.73 Bn | 463.16 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 376.02 Bn | 368.88 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn | 321.00 Mn |
| 5 | Astrazeneca | 257.79 Bn | 252.89 Bn | 12.86 Bn | 1.86 Bn |
| 6 | Amgen | 236.51 Bn | 222.53 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 182.32 Bn | 179.14 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 159.52 Bn | 147.82 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Gsk | 106.18 Bn | 102.01 Bn | 8.24 Bn | -440.07 Mn |
| 10 | Sanofi | 55.17 Bn | 47.79 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 322.00 Mn |
| Jun 30, 2026 | 322.00 Mn |
| Mar 31, 2026 | 265.00 Mn |
| Mar 31, 2026 | 265.00 Mn |
| Dec 31, 2025 | 329.00 Mn |
| Dec 31, 2025 | 329.00 Mn |
| Sep 30, 2025 | 381.00 Mn |
| Sep 30, 2025 | 381.00 Mn |
| Jun 30, 2025 | 269.00 Mn |
| Jun 30, 2025 | 269.00 Mn |
| Mar 31, 2025 | 235.00 Mn |
| Mar 31, 2025 | 235.00 Mn |
| Dec 31, 2024 | 291.00 Mn |
| Dec 31, 2024 | 291.00 Mn |
| Sep 30, 2024 | 249.00 Mn |
| Sep 30, 2024 | 249.00 Mn |
| Jun 30, 2024 | 241.00 Mn |
| Jun 30, 2024 | 241.00 Mn |
| Mar 31, 2024 | 193.00 Mn |
| Mar 31, 2024 | 193.00 Mn |